Regeneron To Showcase Progress In Advancing Novel Investigational Treatment Approaches For A Broad Range Of Solid Tumors And Blood Cancers At ASCO
Regeneron To Showcase Progress In Advancing Novel Investigational Treatment Approaches For A Broad Range Of Solid Tumors And Blood Cancers At ASCO
Oral presentation will feature new data for investigational REGN7075, an EGFRxCD28 costimulatory bispecific with the potential to enhance the treatment of certain advanced solid tumors in combination with Libtayo (cemiplimab-rwlc)
口頭陳述將介紹正在研究的 REGN7075 的新數據，這是一種 egfrxCD28 共刺激雙特異性，與 Libtayo（cemiplimab-rwlc）聯合使用有可能增強某些晚期實體瘤的治療
17 presentations to highlight Regeneron's investigational pipeline including checkpoint inhibitors, CD3 bispecifics and CD28 costimulatory bispecifics
17 場演講，重點介紹了 Regeneron 的研究產品線，包括檢查點抑制劑、CD3 雙特異性和 CD28 共刺激雙特異性
TARRYTOWN, N.Y., April 24, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced new and updated data from its oncology and hematology pipeline will be shared across 17 presentations at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting, taking place from May 31 to June 5 in Chicago, IL. Notably, new safety and efficacy results from a Phase 1/2 trial investigating the costimulatory bispecific antibody REGN7075 (EGFRxCD28) in combination with Libtayo in patients with certain advanced solid tumors will be featured in an oral presentation.
紐約州塔裏敦，2024年4月24日（GLOBE NEWSWIRE）——Regeneron Pharmicals, Inc.（納斯達克股票代碼：REGN）今天宣佈，將在5月31日至6月5日在伊利諾伊州芝加哥舉行的美國臨床腫瘤學會（ASCO）2024年年會上的17場演講中分享其腫瘤學和血液學產品線中的最新和更新數據。值得注意的是，一項研究共刺激雙特異性抗體 REGN7075（EGFRxCD28）與Libtayo聯合治療某些晚期實體瘤患者的1/2期試驗的新安全性和有效性結果將在口頭陳述中介紹。
"The breadth of our presentations at ASCO showcase our progress in advancing multiple promising and distinct investigational treatment approaches for a diverse array of difficult-to-treat cancers," said George D. Yancopoulos, M.D., Ph.D., Board co-Chair, President and Chief Scientific Officer at Regeneron. "These latest clinical results build on our ongoing commitment to cancer research and reflect our focus on advancing a pipeline of internally-developed candidates that have the potential to offer novel and differentiated therapies. Poised to tackle more than 30 types of cancer, our oncology pipeline is a testament to Regeneron's relentless commitment to transforming cancer care for those who need it most."
Regeneron董事會聯席主席、總裁兼首席科學官George D. Yancopoulos醫學博士、博士表示：“我們在ASCO的演講內容廣泛，展示了我們在針對各種難以治療的癌症推進多種前景看好、截然不同的研究性治療方法方面取得的進展。”“這些最新的臨床結果建立在我們對癌症研究的持續承諾基礎上，反映出我們專注於推進內部開發的候選藥物管線，這些候選藥物有可能提供新的差異化療法。我們的腫瘤產品線有望應對30多種癌症，這證明了Regeneron不懈地致力於爲最需要的人改造癌症醫療服務。”
Beyond the REGN7075 data, additional presentations will feature results from Regeneron's diverse pipeline of checkpoint inhibitors and bispecific antibodies. Among them are presentations on updated data and new analyses for linvoseltamab (BCMAxCD3) in multiple myeloma; odronextamab (CD20xCD3) in several lymphoma subtypes; REGN6569 (GITR) in combination with Libtayo across solid tumors; and fianlimab (LAG-3 inhibitor) in combination with Libtayo in non-small cell lung cancer, melanoma and head and neck cancer.
除了 REGN7075 數據外，其他演講還將介紹 Regeneron 各種檢查點抑制劑和雙特異性抗體產品線的結果。其中包括關於多發性骨髓瘤中林沃司他單抗（bcmaxCD3）的更新數據和新分析的演講；幾種淋巴瘤亞型中的奧多瑞克他單抗（CD20xCD3）；與Libtayo聯合治療實體瘤的 REGN6569（GITR）；以及非利單抗（LAG-3 抑制劑）與利布塔約聯合治療非小細胞肺癌、黑色素瘤和頭部腫瘤的最新數據和新分析還有頸部癌。
Regeneron presentations at ASCO:
Regeneron 在 ASCO 的演講：
| Medicine | Abstract title | Abstract | Lead author |
Presentation date/time (all CDT) |
| Solid Tumor Malignancies | ||||
| REGN7075, Libtayo |
A Phase 1/2 study of REGN7075 in combination with cemiplimab in patients with advanced solid tumors: Updated dose escalation results | #2503 Oral Presentation Session— Developmental Therapeutics—Immunotherapy |
Segal, N.H. | Monday, June 3 11:30 a.m. – 2:30 p.m. |
| REGN6569, Libtayo |
A Phase 1 study of REGN6569, a GITR mAb, in combination with cemiplimab in patients (pts) with advanced solid tumor malignancies: Initial dose-escalation results | #2650 Poster Presentation Session— Developmental Therapeutics—Immunotherapy |
Lakhani, N.J. | Saturday, June 1 9:00 a.m. – 12:00 p.m. |
| Blood Cancer | ||||
| Linvoseltamab | Indirect comparison of linvoseltamab (linvo) versus teclistamab (tec) for treatment of triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM) | #7560 Poster Presentation Session— Hematologic Malignancies—Plasma Cell Dyscrasia |
Jagannath, S. | Monday, June 3 9:00 a.m. – 12:00 p.m. |
| Linvoseltamab | Comparative effectiveness of linvoseltamab (Linvo) vs. standard of care (SOC) in real-world patients (pts) with triple class exposed (TCE) relapsed/refractory multiple myeloma (RRMM) | #7561 Poster Presentation Session— Hematologic Malignancies—Plasma Cell Dyscrasia |
Kumar, S. | Monday, June 3 9:00 a.m. – 12:00 p.m. |
| Odronextamab | Phase 3 trial evaluating the efficacy and safety of odronextamab versus investigator's choice in previously untreated follicular lymphoma (OLYMPIA-1) | #7096 Poster Presentation Session— Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia |
Birhiray, R. | Monday, June 3 9:00 a.m. – 12:00 p.m. |
| Odronextamab | Phase 3 trial evaluating the efficacy and safety of odronextamab plus chemotherapy versus rituximab plus chemotherapy in previously untreated follicular lymphoma (OLYMPIA-2) | #7099 Poster Presentation Session— Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia |
Hardin, C. | Monday, June 3 9:00 a.m. – 12:00 p.m. |
| Odronextamab |
Phase 3 trial evaluating efficacy and safety of odronextamab plus CHOP vs rituximab plus CHOP in previously untreated diffuse large B-cell lymphoma (DLBCL; OLYMPIA-3) | #7086 Poster Presentation Session— Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia |
Matasar, M. | Monday, June 3 9:00 a.m. – 12:00 p.m. |
| Odronextamab | Phase 3 trial evaluating the efficacy and safety of odronextamab versus standard-of-care (SOC) therapy in relapsed/refractory (R/R) aggressive B-cell non-Hodgkin lymphoma (B-NHL;OLYMPIA-4) | #7093 Poster Presentation Session— Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia |
Hawkes, E.A. | Monday, June 3 9:00 a.m. – 12:00 p.m. |
| Odronextamab |
Phase 3 trial of odronextamab plus lenalidomide versus rituximab plus lenalidomide in relapsed/refractory (R/R) follicular lymphoma (FL) and marginal one lymphoma (MZL; (OLYMPIA-5) | #7094 Poster Presentation Session— Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia |
Vitolo, U. | Monday, June 3 9:00 a.m. – 12:00 p.m. |
| Odronextamab | Results from the follicular lymphoma (FL) outcomes in relapsed/refractory (R/R) patients treated with systemic therapy in a real-world assessment (FLORA) study | #7076 Poster Presentation Session— Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia |
Luminari, S. | Monday, June 3 9:00 a.m. – 12:00 p.m. |
| Skin Cancer | ||||
| Fianlimab, Libtayo | A Phase 3 trial of fixed dose combinations of fianlimab (anti-LAG-3) + cemiplimab (anti-PD-1) versus relatlimab + nivolumab in patients with unresectable or metastatic melanoma | #TPS9611 Poster Presentation Session— Melanoma/Skin Cancers |
Khushalani, N.I. | Saturday, June 1 1:30 p.m. – 4:30 p.m. |
| Lung Cancer | ||||
| Fianlimab, Libtayo |
A Phase 2/3 study of fianlimab, cemiplimab, plus chemotherapy versus cemiplimab plus chemotherapy in first-line advanced non-small cell lung cancer | #TPS8660 Poster Presentation Session— Lung Cancer—Non-Small Cell Metastatic |
Gabrail, N. | Monday, June 3 1:30 p.m. – 4:30 p.m |
| Fianlimab, Libtayo | A Phase 2/3 study of fianlimab plus cemiplimab versus cemiplimab in patients with advanced non-small cell lung cancer with tumors expressing PD-L ≥50% | #TPS8663 Poster Presentation Session— Lung Cancer—Non-Small Cell Metastatic |
Faulkner, N. | Monday, June 3 1:30 p.m. – 4:30 p.m. |
| Gynecologic Cancer | ||||
| Libtayo | Combination of cemiplimab and ISA101b vaccine for the treatment of recurrent/metastatic HPV16 cervical cancer* | #5522 Poster Presentation Session— Gynecologic Cancer |
Lorusso, D. | Monday, June 3 9:00 a.m. – 12:00 p.m. |
| Ubamatamab, Libtayo | A Phase 1/2 study of ubamatamab (REGN4018), a MUC16×CD3 bispecific antibody, administered alone or in combination with cemiplimab (anti–PD-1) in patients with recurrent ovarian cancer or MUC16+ endometrial cancer: Trial in progress update | #TPS5632 Poster Presentation Session— Gynecologic Cancer |
Nieuwenhuysen, E. | Monday, June 3 9:00 a.m. – 12:00 p.m. |
| Head and Neck Cancer | ||||
| Fianlimab, Libtayo |
A Phase 1 study of fianlimab (anti-LAG-3) in combination with cemiplimab (anti-PD-1) in patients with advanced HNSCC | #6038 Poster Presentation Session— Head and Neck Cancer |
Cho, B.C. | Sunday, June 2 9:00 a.m. – 12:00 p.m. |
| DB-020 | A phase 1 clinical trial of DB-020 intratympanic injections administered prior to high dose cisplatin chemotherapy to reduce ototoxicity | #6100 Poster Presentation Session— Head and Neck Cancer |
Rischin, D. | Sunday, June 2 9:00 a.m. – 12:00 p.m. |
| 醫學 | 摘要標題 | 摘要 | 主要作者 | 演示日期/時間 （全部爲 CDT） |
| 實體瘤惡性腫瘤 | ||||
| REGN7075，Libtayo |
REGN7075 聯合西米普利單抗治療晚期實體瘤患者的 1/2 期研究：最新劑量遞增結果 | #2503 口頭演講 會議—發育療法—免疫療法 |
新罕布什爾州西格爾 | 6月星期一 3 上午 11:30 — 下午 2:30 |
| REGN6569，Libtayo |
GITR 單抗 REGN6569 與塞米普利單抗聯合治療晚期實體瘤惡性腫瘤患者（pts）的 1 期研究：初步劑量遞增結果 | #2650 海報演示 會議—發育療法—免疫療法 |
新澤西州拉哈尼 | 6月星期六 1 上午 9:00 — 下午 12:00 |
| 血液癌 | ||||
| Linvoseltamab | 用於治療三類暴露 (TCE) 復發/難治性多發性骨髓瘤 (RRMM) 的 linvoseltamab (linvo) 與 teclistamab (tec) 的間接比較 | #7560 海報演示 會議—血液系統惡性腫瘤—漿細胞異常 |
賈甘納特，S. | 6月星期一 3 上午 9:00 — 下午 12:00 |
| Linvoseltamab | linvoseltamab（Linvo）與標準護理（SOC）對現實世界中三類暴露（TCE）復發/難治性多發性骨髓瘤（RRMM）患者（pts）的比較療效 | #7561 海報演示 會議—血液系統惡性腫瘤—漿細胞異常 |
庫馬爾，S. | 6月星期一 3 上午 9:00 — 下午 12:00 |
| Odronextamab | 評估Odronextamab與研究者選擇的治療先前未經治療的濾泡性淋巴瘤（OLYMPIA-1）的療效和安全性對比的3期試驗 | #7096 海報演示 會議—血液系統惡性腫瘤—淋巴瘤和慢性淋巴細胞白血病 |
Birhiray，R. | 6月星期一 3 上午 9:00 — 下午 12:00 |
| Odronextamab | 評估奧多奈單抗聯合化療對比利妥昔單抗聯合化療對先前未經治療的濾泡性淋巴瘤（OLYMPIA-2）的療效和安全性的3期試驗 | #7099 海報演示 會議—血液系統惡性腫瘤—淋巴瘤和慢性淋巴細胞白血病 |
哈丁，C. | 6月星期一 3 上午 9:00 — 下午 12:00 |
| Odronextamab |
評估奧多奈單抗聯合CHOP對比利妥昔單抗加CHOP對先前未經治療的瀰漫性大B細胞淋巴瘤（DLBCL；OLYMPIA-3）的療效和安全性的3期試驗 | #7086 海報演示 會議—血液系統惡性腫瘤—淋巴瘤和慢性淋巴細胞白血病 |
馬塔薩爾，M. | 6月星期一 3 上午 9:00 — 下午 12:00 |
| Odronextamab | 評估復發/難治性（R/R）侵襲性 B 細胞非霍奇金淋巴瘤（B-NHL；OLYMPIA-4）中 odronextamab 與標準護理（SOC）療法的療效和安全性的 3 期試驗 | #7093 海報演示 會議—血液系統惡性腫瘤—淋巴瘤和慢性淋巴細胞白血病 |
霍克斯，E.A. | 6月星期一 3 上午 9:00 — 下午 12:00 |
| Odronextamab |
奧多奈單抗聯合來那度胺對比利妥昔單抗加來那度胺治療復發/難治性（R/R）濾泡性淋巴瘤（FL）和邊緣單淋巴瘤（MZL）的3期試驗；（OLYMPIA-5） | #7094 海報演示 會議—血液系統惡性腫瘤—淋巴瘤和慢性淋巴細胞白血病 |
維託洛，U. | 6月星期一 3 上午 9:00 — 下午 12:00 |
| Odronextamab | 現實世界評估（FLORA）研究中接受全身療法治療的復發/難治性（R/R）患者濾泡淋巴瘤（FL）預後的結果 | #7076 海報演示 會議—血液系統惡性腫瘤—淋巴瘤和慢性淋巴細胞白血病 |
Luminari、S. | 6月星期一 3 上午 9:00 — 下午 12:00 |
| 皮膚癌 | ||||
| Fianlimab，Libtayo | 一項針對不可切除或轉移性黑色素瘤患者的固定劑量組合非安利單抗（抗Lag-3）+ cemiplimab（抗PD-1）對比rellimab + nivolumab + nivolumab 的3期試驗 | #TPS9611 海報演示 會議— 黑色素瘤/皮膚癌 |
新澤西州胡沙拉尼 | 6月星期六 1 下午 1:30 — 下午 4:30 |
| 肺癌 | ||||
| Fianlimab， Libtayo |
一項針對一線晚期非小細胞肺癌的非利單抗、塞米普利單抗聯合化療對比塞米普利單抗加化療的2/3期研究 | #TPS8660 海報演示 會議—肺癌—非小細胞轉移 |
加布雷爾，N. | 6月星期一 3 下午 1:30 — 下午 4:30 |
| Fianlimab，Libtayo | 一項針對晚期非小細胞肺癌患者的非利單抗加塞米普利單抗與塞米普利單抗的2/3期研究，其腫瘤表達PD-L ≥ 50% | #TPS8663 海報演示 會議—肺癌—非小細胞轉移 |
福克納，N. | 6月星期一 3 下午 1:30 — 下午 4:30 |
| 婦科癌症 | ||||
| Libtayo | cemiplimab 和 isa101b 疫苗聯合用於治療復發/轉移性 HPV16 宮頸癌* | #5522 海報演示 會議—婦科癌症 |
洛魯索，D. | 6月星期一 3 上午 9:00 — 下午 12:00 |
| Ubamatamab，Libtayo | 對複發性卵巢癌或 MUC16+ 子宮內膜癌患者單獨使用或與塞米普利單抗（抗 PD-1）聯合給藥的 MUC16×CD3 雙特異性抗體ubamatamab（REGN4018）的1/2期研究：正在進行的試驗更新 | #TPS5632 海報演示 會議—婦科癌症 |
Nieuwenhuysen，E. | 6月星期一 3 上午 9:00 — 下午 12:00 |
| 頭頸部癌症 | ||||
| Fianlimab， Libtayo |
非利單抗（抗Lag-3）聯合西米普利單抗（抗PD-1）治療晚期HNSCC患者的1期研究 | #6038 海報演示 會議—頭頸部癌症 |
不列顛哥倫比亞省 Cho | 六月星期日 2 上午 9:00 — 下午 12:00 |
| DB-020 | 一項在高劑量順鉑化療之前進行的 DB-020 鼓膜內注射以降低耳毒性的 1 期臨床試驗 | #6100 海報演示 會議—頭頸部癌症 |
裏辛，D. | 六月星期日 2 上午 9:00 — 下午 12:00 |
*Study conducted in collaboration between Regeneron and ISA.
*Regeneron 和 ISA 合作進行的研究。
The potential uses of Libtayo, REGN7075, odronextamab, linvoseltamab, REGN6569, fianlimab and DB-020 as described above are investigational, and their safety and efficacy in these uses have not been fully evaluated by any regulatory authority. REGN7075, odronextamab, linvoseltamab, REGN6569, fianlimab and DB-020 are not currently approved for use in any indication.
如上所述，Libtayo、REGN7075、odronextamab、linvoseltamab、REGN6569、fianlimab 和 DB-020 的潛在用途尚在研究中，其在這些用途中的安全性和有效性尚未得到任何監管機構的全面評估。REGN7075、奧多瑞他單抗、林沃司他單抗、REGN6569、非安利單抗和 DB-020 目前未獲準用於任何適應症。
譯文內容由第三人軟體翻譯。